Yes, Reglan (metoclopramide) has a black box warning from the FDA stating that use can cause tardive dyskinesia, a serious movement disorder. The risk increases with longer treatment duration and total cumulative dose. Symptoms may not resolve after stopping the drug. If you experience involuntary movements, consult your healthcare provider immediately.
If you or someone you know has taken Reglan and developed involuntary muscle movements, you may be wondering whether the medication caused them. The medical community has long recognized that certain drugs can trigger movement disorders, and this historical understanding provides a framework for evaluating individual cases. This page examines the strength of the evidence linking Reglan to tardive dyskinesia and clarifies what it can and cannot show.
Tardive dyskinesia (TD) is characterized by involuntary, repetitive movements, typically of the face, tongue, and extremities. The condition can be disfiguring and may persist even after the offending drug is discontinued. According to the prescribing information for Reglan, metoclopramide can cause TD, a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The same source notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Diagnosis of TD relies on clinical observation of these abnormal movements, often using standardized rating scales, and a history of exposure to dopamine-blocking agents like metoclopramide.
The pharmacological basis for Reglan-induced TD lies in its mechanism of action. Metoclopramide is a dopamine D2-receptor blocking agent (https://pubmed.ncbi.nlm.nih.gov/34712535/). By antagonizing dopamine receptors in the brain's basal ganglia, it can disrupt normal motor control pathways. Chronic blockade of D2 receptors is thought to lead to upregulation or supersensitivity of these receptors, which may manifest as the hyperkinetic movements seen in TD. This mechanistic pathway is consistent with other drugs known to cause TD, such as antipsychotics. The risk is not limited to long-term use; a case report describes a gynecological patient who developed dyskinetic movements after a single intraoperative dose of metoclopramide, highlighting that even brief exposure can trigger TD in susceptible individuals (https://pubmed.ncbi.nlm.nih.gov/34712535/). That report also notes that the patient had several risk factors for TD, suggesting that individual vulnerability plays a role.
The risk of developing TD from Reglan is directly linked to duration of treatment and total cumulative dosage. The boxed warning on the label states that the risk increases with duration of metoclopramide treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). To mitigate this risk, Reglan is contraindicated in patients with a history of TD, and the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For symptomatic gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, treatment should also be limited to 12 weeks; if longer use is unavoidable, routine monitoring for signs of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label further advises that Reglan is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The adequacy of warnings regarding Reglan and TD is a critical risk anchor. The prescribing information includes a boxed warning—the strongest type of warning required by the FDA—that explicitly states metoclopramide can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning also instructs prescribers to immediately discontinue Reglan if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, cases of TD continue to occur, sometimes after short-term use, as documented in the medical literature (https://pubmed.ncbi.nlm.nih.gov/34712535/). This raises questions about whether prescribers and patients fully appreciate the risk, especially given that Reglan is often used for common conditions like nausea and gastroparesis.
For affected patients, causation considerations are important. The development of TD after Reglan use is a recognized adverse drug reaction, and the timeline between exposure and harm can vary. While the risk increases with longer treatment, cases have been reported after a single dose (https://pubmed.ncbi.nlm.nih.gov/34712535/). Patients who develop TD may face a condition that is potentially irreversible, impacting quality of life. The label advises that if symptoms occur, Reglan should be discontinued and immediate medical attention sought (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, even after discontinuation, TD may persist. In summary, the evidence clearly establishes that Reglan (metoclopramide) can cause tardive dyskinesia through its dopamine-blocking mechanism. The risk is dose- and duration-dependent, but cases can occur after short exposure. Regulatory warnings are in place, but the potential for harm remains, emphasizing the need for careful prescribing and monitoring.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tardive dyskinesia (TD) is a potentially irreversible movement disorder characterized by involuntary, repetitive movements, often of the face, tongue, and extremities. Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause TD by disrupting normal motor control pathways in the brain. The risk increases with longer treatment duration and higher cumulative doses, but cases have been reported even after a single dose.
The FDA has issued a boxed warning—the strongest type of warning—for Reglan, stating that metoclopramide can cause tardive dyskinesia, a potentially irreversible serious movement disorder. The warning advises that the risk increases with duration of treatment and total cumulative dosage, and that Reglan should be used for the shortest duration necessary. If signs or symptoms of TD develop, the drug should be discontinued immediately.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.